185 related articles for article (PubMed ID: 28385379)
21. Utility of Adjuvant Chemotherapy After Neoadjuvant Chemoradiation and Esophagectomy for Esophageal Cancer.
Burt BM; Groth SS; Sada YH; Farjah F; Cornwell L; Sugarbaker DJ; Massarweh NN
Ann Surg; 2017 Aug; 266(2):297-304. PubMed ID: 27501170
[TBL] [Abstract][Full Text] [Related]
22. Genetic prediction of long-term survival after neoadjuvant chemoradiation in locally advanced esophageal cancer.
Gusella M; Giacopuzzi S; Bertolaso L; Zanoni A; Pezzolo E; Modena Y; Menon D; Paganin P; Weindelmayer J; Crepaldi G; De Manzoni G; Pasini F
Pharmacogenomics J; 2017 Jun; 17(3):252-257. PubMed ID: 26927287
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center.
Zanoni A; Verlato G; Giacopuzzi S; Weindelmayer J; Casella F; Pasini F; Zhao E; de Manzoni G
Ann Surg Oncol; 2013 Jun; 20(6):1993-9. PubMed ID: 23274533
[TBL] [Abstract][Full Text] [Related]
24. P53 and SOX2 Protein Expression Predicts Esophageal Adenocarcinoma in Response to Neoadjuvant Chemoradiotherapy.
van Olphen SH; Biermann K; Shapiro J; Wijnhoven BP; Toxopeus EL; van der Gaast A; Stoop HA; van Lanschot JJ; Spaander MC; Bruno MJ; Looijenga LH
Ann Surg; 2017 Feb; 265(2):347-355. PubMed ID: 28059963
[TBL] [Abstract][Full Text] [Related]
25. Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma.
Wagener-Ryczek S; Schoemmel M; Kraemer M; Bruns C; Schroeder W; Zander T; Gebauer F; Alakus H; Merkelbach-Bruse S; Buettner R; Loeser H; Thelen M; Schlößer HA; Quaas A
Cancer Immunol Immunother; 2020 Apr; 69(4):523-533. PubMed ID: 31960110
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant chemoradiotherapy improves histological results compared with perioperative chemotherapy in locally advanced esophageal adenocarcinoma.
Luc G; Vendrely V; Terrebonne E; Chiche L; Collet D
Ann Surg Oncol; 2015 Feb; 22(2):604-9. PubMed ID: 25169119
[TBL] [Abstract][Full Text] [Related]
27. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
Schneider S; Uchida K; Brabender J; Baldus SE; Yochim J; Danenberg KD; Salonga D; Chen P; Tsao-Wei D; Groshen S; Hoelscher AH; Schneider PM; Danenberg PV
J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
[TBL] [Abstract][Full Text] [Related]
28. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer.
Xi H; Baldus SE; Warnecke-Eberz U; Brabender J; Neiss S; Metzger R; Ling FC; Dienes HP; Bollschweiler E; Moenig S; Mueller RP; Hoelscher AH; Schneider PM
Clin Cancer Res; 2005 Dec; 11(23):8341-7. PubMed ID: 16322294
[TBL] [Abstract][Full Text] [Related]
29. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma.
Rizk NP; Venkatraman E; Bains MS; Park B; Flores R; Tang L; Ilson DH; Minsky BD; Rusch VW;
J Clin Oncol; 2007 Feb; 25(5):507-12. PubMed ID: 17290058
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant chemotherapy or chemoradiotherapy for locally advanced esophageal cancer.
Smithers BM; Thomson I
Thorac Surg Clin; 2013 Nov; 23(4):509-23. PubMed ID: 24199701
[TBL] [Abstract][Full Text] [Related]
31. Primary tumor microRNA signature predicts recurrence and survival in patients with locally advanced esophageal adenocarcinoma.
Matsui D; Zaidi AH; Martin SA; Omstead AN; Kosovec JE; Huleihel L; Saldin LT; DiCarlo C; Silverman JF; Hoppo T; Finley GG; Badylak SF; Kelly RJ; Jobe BA
Oncotarget; 2016 Dec; 7(49):81281-81291. PubMed ID: 27793030
[TBL] [Abstract][Full Text] [Related]
32. Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapy.
Taylor Ripley R; Surman DR; Diggs LP; Trepel JB; Lee MJ; Ryan J; Davis JL; Steinberg SM; Hernandez JM; Hoang C; Kenney CM; Bond CD; Kunst TF; Letai A; Schrump DS
BMC Gastroenterol; 2018 Jun; 18(1):94. PubMed ID: 29933761
[TBL] [Abstract][Full Text] [Related]
33. Treatment of clinical T2N0M0 esophageal cancer.
Hardacker TJ; Ceppa D; Okereke I; Rieger KM; Jalal SI; LeBlanc JK; DeWitt JM; Kesler KA; Birdas TJ
Ann Surg Oncol; 2014 Nov; 21(12):3739-43. PubMed ID: 25047477
[TBL] [Abstract][Full Text] [Related]
34. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-17 is downregulated in esophageal adenocarcinoma cancer stem-like cells and promotes a radioresistant phenotype.
Lynam-Lennon N; Heavey S; Sommerville G; Bibby BA; Ffrench B; Quinn J; Gasch C; O'Leary JJ; Gallagher MF; Reynolds JV; Maher SG
Oncotarget; 2017 Feb; 8(7):11400-11413. PubMed ID: 28002789
[TBL] [Abstract][Full Text] [Related]
36. Long-term outcomes following neoadjuvant chemoradiotherapy in patients with clinical T2N0 esophageal squamous cell carcinoma.
Chen WH; Chao YK; Chang HK; Tseng CK; Wu YC; Liu YH; Hsieh MJ; Liu HP
Dis Esophagus; 2012 Apr; 25(3):250-5. PubMed ID: 21951719
[TBL] [Abstract][Full Text] [Related]
37. Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.
Cho HJ; Kim YH; Kim HR; Kim DK; Park SI; Kim JH; Kim SB
Ann Surg Oncol; 2015; 22(6):1851-7. PubMed ID: 25344308
[TBL] [Abstract][Full Text] [Related]
38. Is There a Correlation Between Clinical Complete Response and Pathological Complete Response After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Cancer?
Liu SL; Xi M; Yang H; Yang YD; Wu YJ; Zhao L; Zhang P; Luo LL; Liu MZ
Ann Surg Oncol; 2016 Jan; 23(1):273-81. PubMed ID: 26215200
[TBL] [Abstract][Full Text] [Related]
39. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
Barbour AP; Jones M; Gonen M; Gotley DC; Thomas J; Thomson DB; Burmeister B; Smithers BM
Ann Surg Oncol; 2008 Oct; 15(10):2894-902. PubMed ID: 18663531
[TBL] [Abstract][Full Text] [Related]
40. Emerging therapeutic targets in esophageal adenocarcinoma.
Gaur P; Hunt CR; Pandita TK
Oncotarget; 2016 Jul; 7(30):48644-48655. PubMed ID: 27102294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
